Hopes Pinned On Boston Scientific Corporation (NYSE:BSX)’s Innova
Boston Scientific Corporation (NYSE:BSX) is launching an important clinical trial that will serve as a base for the global regulatory-approvals that it requires for Innova, the drug eluting stent system. A doctor in New Zealand has now performed the first patient-implant of this stent.
This trial has been designed to judge the performance and safety of the 1st Boston Scientific Corporation (NYSE:BSX) peripheral drug-eluting stent-system. The expectation is that 55 patients will be enrolled in 15 centers across Australia, Europe and New Zealand.
The first surgery
This system has been designed to restore the flow of blood in the arteries that lie above the knee. It aims at the proximal popliteal artery and the SFA. The stent is a unique combination of drug polymer. It is intended to facilitate the optimum-release of the drug which will help prevent narrowing of the vessel. Andrew Holden, M.D who is the director of Interventional Radiology at the Auckland City Hospital in Auckland, New Zealand performed the first surgery.
In Wednesday’s trading, Boston Scientific Corporation (NYSE:BSX) rose by 2.27%. The opening price of the shares was $11.48, which climbed to an intraday high of $11.79 and dipped to a close of $11.72. Approximately 15.54 million shares were traded on Wednesday while an average volume of 14.96 million shares were traded over a 30 day period. The 52-week low of Boston Scientific Corporation (NYSE:BSX) shares is $5.04 and its 52-week high is $12.16.
About the company
Boston Scientific Corporation (NYSE:BSX) is a company that develops, manufactures and markets various medical devices that are used in a variety of interventional-medical specialties. In the year ended 31 December 2011, the company’s products were sold via 7 core businesses: 1) Interventional Cardiology, 2) CRM, 3) Endoscopy, 4) Peripheral Interventions, 5) Urology/Women’s Health, 6) Neuromodulation, and 7) Electrophysiology